Sessions Shaped By Member Preference Survey | ASRS 2025
Surveys of American Society of Retina Specialists members have revealed a preference for physicians’ experiences with new therapies, rather than summaries of clinical trial data, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
Sessions at the American Society of Retina Specialists 2025 meeting will focus on new study results rather than repetitive long-term study results, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.
Shah cited member feedback from previous meetings.
“Our members have clearly stated to us that they're interested in new things, new trials, and new drugs,” Shah said in a recent video interview with Managed Healthcare Executive. “Physicians are interested in the results of an investigator-sponsored trial with a drug, rather than a rehash of a subgroup analysis.”
Gaurav K. Shah, M.D.
Shah drew on his experience as a physician. He currently practices ophthalmology at West Coast Retina, located in San Francisco.
“I would much rather believe, ‘I tried this drug on 64 patients of mine, and this is what I found,’ not what a statistician found.”
The 43rd annual ASRS takes place from July 30 to August 2, 2025, at the Long Beach Convention Center in Long Beach, California.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
First-in-Class Therapy for Diabetic Retinopathy Shows Six-Month Benefit | ASRS 2025
July 31st 2025PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block endothelin signaling to increase ocular blood flow and prevent vision loss.
Read More
Changes to Susvimo Port Delivery System Explained | ASRS 2024
July 31st 2025Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.
Read More
Results from retrospective real-world studies presented at American Society of Retina Specialists annual meetiing put the risk of retinal vasculitis from Syfovre at 1 in 1,330 patients. But other results presented at the meeting supplied evidence that Syfovre fends off vision loss caused by geographic atrophy, an advanced form of dry age-related macular degeneration.
Read More
